NEW YORK (GenomeWeb) – Vela Diagnostics today announced a collaboration with France's Gustave Roussy Institute of Oncology on next-generation based cancer testing.

The collaboration will focus on both solid and liquid tumor diagnostics using Vela's Sentosa NGS platform. Gustave Roussy, located just outside Paris, recently implemented the Sentosa platform to diagnose melanoma, colorectal cancer, and non-small cell lung cancer.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.